Abstracts Archive - Page 246 of 2425 - ACR Meeting Abstracts

Abstract Number: 0806 • ACR Convergence 2023
Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Linda Li¹, Hui Xie², Lynne feehan¹, Na Lu³, Alison Hoens⁴, Kelly English⁵, Eileen Davidson⁵, Catherine L. Backman⁶, Smruthi Ramachandran¹, Ellen Wang¹, Stephanie Therrien³, Julia Mucha¹, Teresa Liu-Ambrose¹, Kimberly Miller⁷, Christopher Shaw⁸ and Diane Lacaille⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board, Arthritis Research Canada, Vancouver, BC, Canada, ⁶The University of British Columbia, Vancouver, BC, Canada, ⁷BC Children’s and Women’s Hospital & Health Centre, Vancouver, BC, Canada, ⁸Simon Fraser University, Burnaby, BC, Canada, ⁹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To achieve optimal health outcomes, people with rheumatoid arthritis (RA) need to know their symptom patterns and be able to practice self-care activities. With…
Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Leah Medrano and Alice Hoftman, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…
Abstract Number: 1203 • ACR Convergence 2023
Vaccination Against SARS-CoV-2 in Inflammatory Arthritis and Factors Determining Its Decision
Olivier FAKIH¹, Charlotte Bourgoin², Violette Benier¹, Thomas Lohse¹, Cerise Guillochon¹, Elodie Bouvier², Jean-Charles Balblanc¹, Thierry Conrozier¹ and Anne Lohse¹, ¹Service de rhumatologie, Hôpital Nord Franche-Comté, Trévenans, France, ²Unité de recherche clinique, Hôpital Nord Franche-Comté, Trévenans, France
Background/Purpose: DMARDs, which are essential for controlling the progression of inflammatory arthritis (IA), are mostly immunomodulators that significantly increase the risk of severe infections. Therefore,…
Abstract Number: 1192 • ACR Convergence 2023
Autoimmune Thyroid Disease Associates with Symptomatic Hand Osteoarthritis in Older Persons in the Third National Health and Nutrition Examination Survey
Clement Tagoe¹ and Wanyi Wang², ¹Albert Einstein College of Medicine, Bronx, NY, ²Elite Research, LLC, Irving, TX
Background/Purpose: Osteoarthritis (OA) of the hand is associated with the presence of bony deformities in the proximal interphalangeal joints, distal interphalangeal joints, and first carpometacarpal…
Abstract Number: 1031 • ACR Convergence 2023
Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System
Joseph Kim¹, Song Zhang² and Elizabeth Blair Solow¹, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality, particularly if RA is poorly controlled. The effects of socioeconomic deprivation have not been…
Abstract Number: 1037 • ACR Convergence 2023
Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy
Adwoa Dansoa Tabi-Amponsah¹, Sarah Stewart², Greg Gamble¹, Anthony Doyle³, Chang-Nam Son⁴, Kieran Latto¹, Lisa Stamp⁵, William Taylor⁶, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Auckland University of Technology, Auckland, New Zealand, ³Auckland District Health Board and University of Auckland, Auckland, New Zealand, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, UIJEONGBU, South Korea, ⁵University of Otago, Christchurch, New Zealand, ⁶University of Otago, Wellington, New Zealand
Background/Purpose: Preliminary gout remission criteria have been developed using OMERACT core outcome domains for long-term gout studies. This study aimed to identify variables that predict…
Abstract Number: 1176 • ACR Convergence 2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Jiri Vencovsky¹, Jolie Feldman², Lisa McConnachie² and Brendan M. Johnson², ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM), an idiopathic inflammatory myopathy, is a chronic and often debilitating condition characterized by a hallmark skin rash (e.g., Gottron's sign and heliotrope…
Abstract Number: 1196 • ACR Convergence 2023
Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies
Zubeyir Salis¹ and Amanda Sainsbury², ¹The University of New South Wales, Kensington, Australia, ²The University of Western Australia, Crawley, Australia
Background/Purpose: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly prescribed for short-term management of symptoms of knee osteoarthritis (KOA), but they are often used long-term, and the…
Abstract Number: 1197 • ACR Convergence 2023
Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial
Schnitzer Thomas¹, Helene Rovsing², Edith Lau³, Sidsel Boll⁴, Ballari Brahmachari⁵, Richard Chou⁶, Tarini Joshi⁵, Roni Wechsler⁷, Siu-Long Yao⁵, Sveta Weiner⁵, Asger Bihlet⁸ and Philip Conaghan⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Sanos Clinic, Gandrup, Denmark, ³Hong Kong Center for Clinical Research, Hong Kong, China, ⁴Sanos Clinic, Vejle, Denmark, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, ⁷Moebius Medical, Tel Aviv, Israel, ⁸NBCD, Soeborg, Denmark, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Safe and effective therapies are needed for OA pain. MM-II, a novel suspension of large, empty, multilamellar liposomes composed of dimyristoylphosphatidylcholine and dipalmitoylphosphatidylcholine, effectively…
Abstract Number: 1201 • ACR Convergence 2023
Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², David Kane³ and Richard Conway⁴, ¹St James's Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…
Abstract Number: 0739 • ACR Convergence 2023
Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis
Sali Merjanah¹, Devin Driscoll², Christine Peloquin³, Jean liew³ and Maureen Dubreuil⁴, ¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ²Boston University/Boston Medical Center, Boston, MA, ³Boston University, Boston, MA, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…
Abstract Number: 1039 • ACR Convergence 2023
Cross-Sectional Associations of Ultrasound Features with Symptom Outcomes at the Knee: A Community-based Study
Katherine Yates¹, Carolina Alvarez², Todd Schwartz³, Serena Savage-Guin⁴, Jordan Renner⁴, Catherine Bakewell⁵, Minna Kohler⁶, Janice Lin⁷, Jonathan Samuels⁸ and Amanda Nelson⁴, ¹University of North Carolina Medical Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Stanford University, Palo Alto, CA, ⁸NYU Langone, Rye Brook, NY
Background/Purpose: Ultrasound (US) allows for visualization of many features of knee osteoarthritis (KOA) including osteophytes, meniscal extrusion, synovitis, and articular cartilage damage. Additionally, US is…
Abstract Number: 1179 • ACR Convergence 2023
Rituximab in the Treatment of Interstitial Lung Disease Associated with the Antisynthetase Syndrome
Javier Narvaez¹, Elena Cañadillas-Sanchez², Ivan Castellvi³, Juan José Alegre⁴, Paola Vidal-Montal⁵ and Joan Miquel Nolla⁵, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁴Department of Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue therapy in patients with antisynthetase syndrome and interstitial lung disease (ASS-ILD). Methods:…
Abstract Number: 1066 • ACR Convergence 2023
Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples
Kelly Chun and Jane Yang, Labcorp, Calabasas, CA
Background/Purpose: Biologic therapeutic drug monitoring (TDM) of TNF-inhibitor drug and anti-drug antibody provides patient-specific pharmacokinetic and immunogenic assessment. In suboptimal response, drug and anti-drug antibody…
Abstract Number: 1061 • ACR Convergence 2023
Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Chani-mi Lee¹, Margaret Wang², Aarthi Rajkumar¹, Cassandra Calabrese³ and Leonard Calabrese³, ¹University Hospital, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].